|Articles|August 15, 2002

Pending FDA approval: Cardinal Health to ready formulation for market

Irvine, CA-ISTA Pharmaceuticals and Cardinal Health will manufacture commercial quantities of Vitrase, a proprietary formulation of highly purified hyaluronidase, pending its FDA approval.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME